Cargando…

Novel Methods for Clinical Risk Stratification in Patients with Colorectal Liver Metastases

PURPOSE: Colorectal cancer patients with liver-confined metastases are classified as stage IV, but their prognoses can differ from metastases at other sites. In this study, we suggest a novel method for risk stratification using clinically effective factors. MATERIALS AND METHODS: Data on 566 consec...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ki-Yeol, Kim, Nam Kyu, Cha, In-Ho, Ahn, Joong Bae, Choi, Jin Sub, Choi, Gi-Hong, Lim, Joon Suk, Lee, Kang Young, Baik, Seung Hyuk, Min, Byung Soh, Hur, Hyuk, Roh, Jae Kyung, Shin, Sang Joon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398102/
https://www.ncbi.nlm.nih.gov/pubmed/25483744
http://dx.doi.org/10.4143/crt.2014.066
Descripción
Sumario:PURPOSE: Colorectal cancer patients with liver-confined metastases are classified as stage IV, but their prognoses can differ from metastases at other sites. In this study, we suggest a novel method for risk stratification using clinically effective factors. MATERIALS AND METHODS: Data on 566 consecutive patients with colorectal liver metastasis (CLM) between 1989 and 2010 were analyzed. This analysis was based on principal component analysis (PCA). RESULTS: The survival rate was affected by carcinoembryonic antigen (CEA) level (p < 0.001; risk ratio, 1.90), distribution of liver metastasis (p=0.014; risk ratio, 1.46), and disease-free interval (DFI; p < 0.001; risk ratio, 1.98). When patients were divided into three groups according to PCA score using significantly affected factors, they showed significantly different survival patterns (p < 0.001). CONCLUSION: The PCA scoring system based on CEA level, distribution of liver metastasis, and DFI may be useful for preoperatively determining prognoses in order to assist in clinical decisionmaking and designing future clinical trials for CLM treatment.